{"organizations": [], "uuid": "6a48eb6e8042bd4da277382f3533c044c6d5105f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/05/05/104451152-hepatitis-c-drug-sovaldi.1910x1000.jpg", "site_section": "https://www.cnbc.com/id/10000108/device/rss/rss.html", "section_title": "Health Care", "url": "https://www.cnbc.com/2018/02/07/gilead-fourth-quarter-hepatitis-c-drug-sales-plummet-company-sees-a-further-slowdown.html", "country": "US", "domain_rank": 767, "title": "Gilead fourth-quarter hepatitis C drug sales plummet; company sees a further slowdown", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T14:23:00.000+02:00", "replies_count": 0, "uuid": "6a48eb6e8042bd4da277382f3533c044c6d5105f"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/07/gilead-fourth-quarter-hepatitis-c-drug-sales-plummet-company-sees-a-further-slowdown.html", "ord_in_thread": 0, "title": "Gilead fourth-quarter hepatitis C drug sales plummet; company sees a further slowdown", "locations": [], "entities": {"persons": [{"name": "s. gilead", "sentiment": "none"}, {"name": "brian abrahams", "sentiment": "none"}], "locations": [], "organizations": [{"name": "gilead sciences", "sentiment": "negative"}, {"name": "gilead", "sentiment": "negative"}, {"name": "mizuho securities", "sentiment": "none"}, {"name": "kite pharma", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "rbc capital markets", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Gilead Sciences on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for the current year.\nGilead's shares fell slightly after the closing bell.\nFor full-year 2018, the biotechnology company forecast product sales of $20 billion to $21 billion — including hepatitis C drug sales of $3.5 billion to $4 billion — down from $25.7 billion last year. Gilead projected a 2018 tax rate of 21 percent to 23 percent.\nThe company's forecast implies 2018 earnings per share of $6.15, according to Mizuho Securities. Wall Street analysts, on average, expected 2018 earnings per share of $6.73, according to Thomson Reuters I/B/E/S.\nGilead, which last year paid nearly $12 billion for cancer immunotherapy company Kite Pharma, said it earned $1.78 a share in the fourth quarter excluding one-time items, which beat the average Wall Street estimate of $1.67 a share.\nThe quarterly results were \"generally in line,\" RBC Capital Markets analyst Brian Abrahams said in a research note. \"Most notable news was Gilead's 2018 guidance, where competitive dynamics (plus some market shrinkage) are expected to reduce HCV (hepatitis C virus) sales.\"\nIncluding a $6 billion charge related to U.S. corporate tax changes, Gilead posted a fourth-quarter net loss of $3.87 billion.\nQuarterly sales of hepatitis C drugs totaled $1.5 billion, down from $3.2 billion a year earlier but in line with analysts' forecasts. Sales of antiviral and HIV drug rose to $3.7 billion from $3.4 billion.\nShares of Gilead, which rose 2.5 percent to close at $80.38 in regular trading on the Nasdaq, were down 1 percent at $79.55 after-hours.", "external_links": [], "published": "2018-02-07T14:23:00.000+02:00", "crawled": "2018-02-07T14:39:34.027+02:00", "highlightTitle": ""}